Archive

Magnesium Status and Its Association With Glycemic Control and Diabetes-Related Complications in Type 2 Diabetes Mellitus: A Systematic Review

Lower magnesium status was commonly associated with higher HbA1c and glucose, greater insulin resistance, and retinopathy, neuropathy, nephropathy and vascular disease. The single randomised trial raised serum magnesium without improving insulin sensitivity or glycaemic outcomes.

Endocrinology · Cureus · 1d

Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Explains the small but consistent hemoglobin rise on SGLT2 inhibitors — useful when interpreting falling or stable counts in diabetic and heart-failure patients already on these drugs.

Endocrinology · JAMA · 4d

Remote Endocrinology Support for Primary Care Clinicians Managing Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials

Evidence on remote specialist support for primary-care diabetes care is still uncertain, so don't assume e-consult or tele-endocrinology models improve HbA1c until trials show it.

Endocrinology · Cureus · 4d

Subclinical Hypothyroidism: Who Should Be Treated and Who Can Be Observed?

Most SCH is transient and TSH under 10 rarely needs levothyroxine; repeat TSH in 6-8 weeks before prescribing, and treat if pregnant, symptomatic or TSH rising.

Endocrinology · Cureus · 6d

Efficacy and Safety of Automated Insulin Delivery Systems in Children and Adolescents With Type 1 Diabetes: A Systematic Review of Randomized Controlled Trials

Time in range improved by roughly 7 to 12 percentage points across trials; one showed 11 points (95% CI 7-14) and another 8.7 points (95% CI 7.4-9.9) with a 0.4-point HbA1c fall. Hypoglycaemia did not consistently increase.

Endocrinology · Cureus · 6d

As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags

Ask GLP-1 patients about supplement use — unregulated products marketed for weight loss carry interaction and contamination risks your prescription review won't catch.

Endocrinology · ETHealthworld · 6d

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Adolescents With Obesity: A Retrospective Study

Mean reductions at 32 weeks: body weight -15.20 kg (17.2%), BMI -6.70 kg/m² (19.4%), BMI-SDS -1.08, waist circumference -10.71 cm, systolic BP -8.30 mmHg; glycaemic and lipid parameters also improved (all p < 0.001). No adverse events documented.

Endocrinology · Cureus · 6d

Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.

A triple agonist injection may cut OSA severity in patients who cannot tolerate CPAP — worth knowing before patients ask about it.

Endocrinology · NEJM · 7d

Pituicytoma Presenting With Hypogonadotropic Hypogonadism in a Highly Vascular Sellar and Suprasellar Mass: A Case Report

Total testosterone was 8.9 nmol/L with inappropriately normal LH and FSH. CT angiography showed a hypertrophied right meningo-hypophyseal trunk; only partial debulking was possible, and histopathology confirmed pituicytoma

Endocrinology · Cureus · 8d

Knowledge, Attitudes, and Use of Antidiabetic Medications for Weight Loss Among Adults in Riyadh, Saudi Arabia: A Cross-Sectional Study

76 participants (27.0%) reported using antidiabetic medications for weight loss, mostly Ozempic (55.3%) and Mounjaro (44.7%). Median knowledge score 15.0 (IQR 12.0-18.0); knowledge-attitude correlation weak (Spearman's rho = 0.254, p < 0.001).

Endocrinology · Cureus · 8d

Cryoablation in Thyroid Nodules: Current Evidence, Technical Considerations, and Clinical Applications

Benign nodules: technical success in all, no moderate or severe adverse events, mean volume reduction 42.3%, 65.4%, 68.4% and 63.7% at 1, 3, 6 and 12 months. Papillary cancer: moderate adverse events in 3%, no recurrence over mean 34.8 months.

Endocrinology · Cureus · 8d

Food Noise in Obesity: Current Evidence, Measurement, and Clinical Implications

Patients on GLP-1 agonists often report silencing of intrusive food thoughts; this review helps you name and assess that symptom rather than dismiss it as vague craving.

Endocrinology · Cureus · 9d

When Appearances Deceive: A Silent Somatotroph Macroadenoma Presenting With Acromegaloid Features and Paradoxically Low Insulin-Like Growth Factor-1

Acromegaloid features with low IGF-1 can still be a GH-expressing macroadenoma; don't let normal biochemistry delay pituitary imaging in a patient with cranial nerve palsy.

Endocrinology · Cureus · 9d

Predictors of Successful Prandial Insulin Withdrawal Following the Initiation of Therapy Based on Glucagon-Like Peptide-1 (GLP-1) in Adults With Type 2 Diabetes (T2D): A Systematic Review of Clinical, Biochemical, and Treatment-Related Factors

If you start a GLP-1 in a basal-bolus patient, this maps which clinical and biochemical features predict safely dropping mealtime insulin rather than guessing.

Endocrinology · Cureus · 10d

Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women.

Digital-first GLP-1RA prescribing achieved real-world weight loss in 8,127 women, mostly tirzepatide — evidence you can cite when patients ask whether app-based obesity care actually works.

Endocrinology · Nature Medicine · 12d

Continuous Glucose Monitoring in Non-Insulin-Treated Type 2 Diabetes.

CGM improved glycaemic control in non-insulin-treated type 2 diabetes managed in primary care, supporting wider use beyond insulin-treated patients.

Endocrinology · NEJM · 14d

Obesity tops global health threats by avoidable burden: Lancet Commission

Obesity now outranks other modifiable risks in avoidable DALYs, so weight management deserves the same clinical priority as hypertension and smoking cessation in your practice.

Endocrinology · ETHealthworld · 12 Oct

FSSAI pulls up Dr Reddy's, Nestle Health Science over Celevida claims

If patients on GLP-1 therapy ask about high-protein supplements like Celevida, know the muscle-preservation claims are now contested by FSSAI.

Endocrinology · ETHealthworld · 9 Oct

Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial.

An oral GLP-1 agonist needing no fasting or diet rules could give your type 2 patients injectable-level glycaemic control with a tablet.

Endocrinology · Nature Medicine · 5 Oct

Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.

Semaglutide 1 mg weekly preserved kidney function over 52 weeks in T2D with CKD, supporting a GLP-1 option alongside SGLT2 inhibitors for renal protection.

Endocrinology · Nature Medicine · 1 Oct

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

A dual GLP-1/glucagon agonist may offer added weight and glycaemic benefit over current GLP-1 agonists in patients with obesity and type 2 diabetes.

Endocrinology · NEJM · 1 Oct

When Diabetes Mimics Scleroderma: Cheiroarthropathy and Neuropathic Digital Erosions in Type 2 Diabetes

In long-standing diabetes with waxy, stiff hands, consider cheiroarthropathy before labelling scleroderma — it spares patients unnecessary rheumatology workup and immunosuppression.

Endocrinology · Cureus · 1 Oct

Timing of Growth Hormone Therapy Initiation and Final Adult Height in Idiopathic Short Stature: A Systematic Review

Largest registry analysis of 3,939 prepubertal children found no significant mean gain in near-adult height SDS in the ISS subgroup; late-pubertal cohorts reported final heights of 170.9-173.5 cm in males.

Endocrinology · Cureus · 30 Sept

Preserving Muscle Health During Weight Loss: Evidence Across Lifestyle, Surgical, and Pharmacological Interventions

Caloric restriction reduced weight and fat mass but caused variable fat-free mass loss; greater energy restriction sometimes meant greater lean loss. Higher protein plus resistance exercise best preserved lean tissue. Lean mass loss did not necessarily impair strength or function.

Endocrinology · Cureus · 30 Sept

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Offers an oral GLP-1 option for type 2 diabetes patients at cardiovascular risk, though it only matches insulin glargine rather than reducing events.

Endocrinology · Lancet · 30 Sept

Recurrent Facial Miliaria Crystallina Revealing Underlying Hyperthyroidism: A Report of Two Cases

Recurrent facial miliaria without heat or fever triggers should prompt thyroid function testing, as both reported cases had underlying hyperthyroidism.

Endocrinology · Cureus · 29 Sept

Iatrogenic Cushing Syndrome With Glucocorticoid-Induced Adrenal Insufficiency Following Prolonged Topical Clobetasol Use in an Adolescent

Morning cortisol <30 nmol/L, ACTH <5 ng/L; Synacthen cortisol <30 nmol/L at baseline and 30 minutes, 38 nmol/L at 60 minutes. Adrenal reserve recovered by seven months after stopping clobetasol.

Endocrinology · Cureus · 29 Sept

Treatment-Induced Neuropathy Presenting as Thoracic Radiculopathy and Abdominal Wall Protrusion After Marked Glycemic Improvement With Tirzepatide

HbA1c fell from 11.0% to 6.6% over seven months with 17-pound weight loss; weeks later he developed severe thoracoabdominal neuropathic pain and abdominal wall weakness.

Endocrinology · Cureus · 29 Sept

Associations Among Glycemic Variability, Hypomagnesemia, Thyroid Function, and Albuminuria in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study

Beyond HbA1c, visit-to-visit glucose swings and low magnesium tracked with albuminuria in T2DM, suggesting both as cheap add-on risk markers in Indian clinics.

Endocrinology · Cureus · 29 Sept

Association of the Triglyceride–Glucose Index with Systolic and Diastolic Blood Pressure Among Patients With Type 2 Diabetes Mellitus

A cheap index from routine fasting lipids and glucose may flag T2DM patients heading for hypertension, so you can intensify BP surveillance without extra tests.

Endocrinology · Cureus · 29 Sept

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Triple GIP/GLP-1/glucagon agonism adds another injectable option for patients with obesity and type 2 diabetes who fail current GLP-1 therapy.

Endocrinology · Lancet · 29 Sept

Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.

A triple GIP/GLP-1/glucagon agonist given weekly for 80 weeks produced substantial weight loss in adults with obesity without diabetes, adding a third incretin option beyond current dual agonists.

Endocrinology · NEJM · 29 Sept

Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

An oral GLP-1 agonist taken without fasting or diet rules could offer injection-free glycaemic control for early type 2 diabetes, pending full efficacy and safety data.

Endocrinology · Nature Medicine · 29 Sept

FDA Approves First Treatment for MCT8 Deficiency

First approved therapy for this rare X-linked thyroid hormone transport defect; tiratricol lowers peripheral thyrotoxicosis, so paediatricians and endocrinologists can now offer disease-directed treatment rather than supportive care.

Endocrinology · FDA — Press Announcements · 29 Sept

Association of Serum Magnesium Concentration With Microvascular Complications Among Patients Diagnosed With Type 2 Diabetes Mellitus: An Observational Cross-Sectional Analysis

Low serum magnesium tracked with retinopathy, nephropathy and neuropathy in T2DM patients; consider checking magnesium in poorly controlled diabetes rather than ignoring it.

Endocrinology · Cureus · 28 Sept

Systemic Glucose-Lowering Therapies and Periodontal and Peri-Implant Outcomes in Adults With Type 2 Diabetes Mellitus: A Systematic Review

Evidence on whether SGLT2 inhibitors and other glucose-lowering classes improve periodontal and peri-implant outcomes in your T2DM patients remains sparse, so current choices rest on glycaemic control alone.

Endocrinology · Cureus · 27 Sept

Glycemic Dynamics and Management Strategies in Individuals With Type 1 Diabetes During Ramadan: A Continuous Glucose Monitoring-Based Narrative Review

Glycaemic outcomes were heterogeneous, ranging from deterioration to temporary improvement or stability. Hypoglycaemia exposure did not appear to increase; postprandial hyperglycaemia clustered around the evening and pre-dawn meals was the predominant and most variable challenge.

Endocrinology · Cureus · 26 Sept

IcoSema in Weight Management and Glycaemic Control: A Systematic Review and Meta-Analysis

A weekly insulin-semaglutide combo may cut injections while limiting insulin-related weight gain and hypoglycaemia, but heterogeneous comparators mean efficacy estimates remain uncertain.

Endocrinology · Cureus · 25 Sept

Berry Street, Abbott partner to link Lingo CGM with nutrition coaching

Pairing an OTC CGM with dietitian coaching may improve glycaemic control in prediabetes and obesity, but outcome data are still lacking.

Endocrinology · Fierce Healthcare · 23 Sept

Musculoskeletal Adverse Event Signals Associated With Semaglutide, Liraglutide, and Tirzepatide in the US FDA Adverse Event Reporting System

GLP-1 users may report muscle and joint events; ask about myalgia and lean-mass loss at follow-up, especially in older patients on tirzepatide.

Endocrinology · Cureus · 23 Sept